Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma

Cancer Treatment Reviews

Volumn 36, Issue 1, 2010, Pages 16-23

  Porta, Camillo ^a   Bellmunt, Joaquim ^b   Eisen, Tim ^c   Szczylik, Cezary ^d   Mulders, Peter ^e  

^a Medical Oncology   (Italy)

^b HOSPITAL DEL MAR   (Spain)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d MILITARY INSTITUTE OF MEDICINE   (Poland)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bevacizumab; Everolimus; Patient focused; Renal cell carcinoma; Sorafenib; Sunitinib; Targeted agent; Temsirolimus; Treatment approach

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; EVEROLIMUS; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ABDOMINAL PAIN; ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ASTHENIA; BACKACHE; BLEEDING; BONE METASTASIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRAIN METASTASIS; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; COUGHING; DEPRESSION; DESQUAMATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSPNEA; EPISTAXIS; FATIGUE; FLU LIKE SYNDROME; GRANULOCYTE; HAIR COLOR; HAND FOOT SYNDROME; HEART EJECTION FRACTION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOPHOSPHATEMIA; INFECTION; KIDNEY CARCINOMA; KIDNEY FUNCTION; LEUKOPENIA; LIMB PAIN; LIVER METASTASIS; LUNG INFILTRATE; LUNG PARENCHYMA; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; MEDIASTINUM METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NEUTROPHIL; OVERALL SURVIVAL; PAIN; PERIPHERAL EDEMA; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEINURIA; PRURITUS; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SKIN DISCOLORATION; STOMATITIS; THROMBOCYTOPENIA; THYROID DISEASE; VENOUS THROMBOEMBOLISM; VOMITING; WEIGHT REDUCTION; WELLBEING; XEROSTOMIA;

AGED; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; KIDNEY NEOPLASMS; MIDDLE AGED; PATIENT-CENTERED CARE;

EID: 74849131638     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.09.001     Document Type: Review

References (70)

1. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
2. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
3. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
4. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 (2007) 2103-2111
5. Van Spall H.G., Toren A., Kiss A., and Fowler R.A. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 297 (2007) 1233-1240
6. Rawlins M. Harveian Oration. De testimonio: On the evidence for decisions about the use of therapeutic interventions. ; 2008 [accessed 11.08].
7. Djulbegovic B., Loughran T.P.J., Hornung C.A., et al. The quality of medical evidence in haematology-oncology. Am J Med 106 (1999) 198-205
8. Nexavar summary of product characteristics. ; 2009 [accessed 15.05.09].
9. Sutent summary of product characteristics. ; 2009 [accessed 15.05.09].
10. Torisel summary of product characteristics. ; 2009 [accessed 15.05.09].
11. Avastin summary of product characteristics. ; 2009 [accessed 15.05.2009].
12. Wilhelm S., Carter C., Lynch M., et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5 (2006) 835-844
13. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) [PMID: 19451442]
14. Motzer R.A., Hutson T.E., Tomczac P., et al. Overall survival and updated results for sunitinib compared with interferon (IFN)-alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) [PMID: 19487381]
15. Escudier BJ, Bellmunt J, Negrier S, et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2009;27:15s [suppl; abstr 5020].
16. Rini B.I., Halabi S., Rosenberg J.E., et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: calgb 90206. J Clin Oncol 26 (2008) 5422-5428
17. Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372 (2008) 449-456
18. National Comprehensive Guidelines Network. Kidney cancer. ; 2009 [accessed 05.05.09].
19. Ljungberg B, Hanbury DC, Kuczyk MA, et al. European Association of Urology guidelines on renal cell carcinoma 2008. ; 2009 [accessed 15.05.09].
20. Beck J, Bajetta E, Escudier B, et al. A large open-label, non-comparative, phase III study of the multi-targeted kinase inhibitor sorafenib in European patients with advanced renal cell carcinoma. Presentation at ECCO 14 2007, Barcelona, Spain; 2007.
21. Knox JJ, Figlin RA, Stadler WM, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: safety and efficacy. Presentation at ASCO 2007, Chicago, IL, USA. ; 2009 [accessed 15.05.09].
22. Gore ME, Porta C, Oudard S, et al. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. Presentation at ASCO 2007, Chicago, IL, USA. ; 2009 [accessed 15.05.09].
23. Delahunt B., Bethwaite P.B., and Nacey J.N. Outcome prediction for renal cell carcinoma: evaluation of prognostic factors for tumours divided according to histological subtype. Pathology 39 (2007) 459-465
24. Linehan W.M., Walther M.M., and Zbar B. The genetic basis of cancer of the kidney. J Urol 170 (2003) 2163-2172
25. Motzer R.J., Bacik J., Mariani T., Russo P., Mazumdar M., and Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20 (2002) 2376-2381
26. Henderson CA, Bukowski RM, Stadler WM, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: subset analysis of patients (pts) with brain metastases (BM). J Clin Oncol 2007;25(Suppl.):650s [Abstract 15506].
27. Plimack ER, Jonasch E, Bekele BN, Smith LA, Araujo JC, Tannir NM. Sunitinib in non-clear cell renal cell carcinoma (ncc-RCC): a phase II study. J Clin Oncol 2008;26(Suppl.):277s [Abstract 5112].
28. Dutcher JP, de Souza PL, Figlin R, et al. Effect of temsirolimus versus interferon-a on survival of patients with advanced renal cell carcinoma of different tumour histologies. ASCO GI 2008. ; 2009 [accessed 15.05.09].
29. Motzer R.J., Bacik J., Mariani T., et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20 (2002) 2376-2381
30. Kwak C., Park Y.H., Jeong C.W., Jeong H., Lee S.E., and Ku J.H. Characteristics of metastasis as a prognostic factor for immunotherapy in metastatic renal cell carcinoma. Tumori 93 (2007) 68-74
31. Motzer R.J., Mazumdar M., Bacik J., Berg W., Amsterdam A., and Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 (1999) 2530-2540
32. Escudier B., Szczylik C., Hutson T.E., et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27 (2009) 1280-1289
33. Cho K.S., Choi Y.D., Kim S.J., et al. A comprehensive prognostic stratification for patients with metastatic renal clear cell carcinoma. Yonsei Med J 49 (2008) 451-458
34. Choueiri T.K., Garcia J.A., Elson P., et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110 (2007) 543-550
35. Thyavihally Y.B., Mahantshetty U., Chamarajanagar R.S., Raibhattanavar S.G., and Tongaonkar H.B. Management of renal cell carcinoma with solitary metastasis. World J Surg Oncol 3 (2005) 48
36. Barnholtz-Sloan J.S., Sloan A.E., Davis F.G., Vigneau F.D., Lai P., and Sawaya R.E. Incidence proportions of brain metastases in patients diagnosed (1973-2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22 (2004) 2865-2872
37. Hariharan S, Szczylik C, Bracarda S, et al. Sunitinib in metastatic renal cell carcinoma (mRCC) patients (pts) with brain metastases (mets): data from an expanded access trial. Presentation at ASCO 2008, Chicago, IL, USA. ; 2008 [accessed 15.05.09].
38. Massard C, Zonierek J, Laplanche A, Schwartz B, Szczylik C, Escudier B. Incidence of brain metastasis in advanced renal cell carcinoma among patients randomized in a phase III trial of sorafenib, an oral multi-kinase inhibitor. In: Poster presentation at ESMO 2006, Istanbul, Turkey; 2006 [Abstract 454P].
39. Motzer RJ, Figlin RA, Hutson TE, et al. Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. Presentation at ASCO 2007, Chicago, IL, USA. ; 2009 [accessed 15.05.09].
40. Heng DY, Xie W, Regan M, et al. Prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted agents: results from a large multicenter study. Presentation at ASCO Genitourinary Cancers Symposium 2009. ; 2009 [accessed 10.06.09, abstract 284].
41. Zisman A., Pantuck A.J., Dorey F., et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 19 (2001) 1649-1657
42. Mekhail T.M., bou-Jawde R.M., Boumerhi G., et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 832-841
43. Aapro M.S., Kohne C.H., Cohen H.J., and Extermann M. Never too old? Age should not be a barrier to enrolment in cancer clinical trials. Oncologist 10 (2005) 198-204
44. Bellmunt J., Negrier S., Escudier B., Awada A., and Aapro M. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG taskforce. Crit Rev Oncol Hematol 69 (2009) 64-72
45. Aron M., Nguyen M.M., Stein R.J., and Gill I.S. Impact of gender in renal cell carcinoma: an analysis of the SEER database. Eur Urol 54 (2008) 133-140
46. Gore M.E., Szczylik C., Porta C., et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10 (2009) 757-763
47. Bajetta E, Ravaud A, Bracada S, et al. Efficacy and safety of first-line bevacizumab (BEV) plus interferon-α2a (IFN) in patients (pts) >65 years with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008;26(Suppl.):273s [Abstract 5095].
48. Dutcher JP, Szczylik C, Tannir N, et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). Presentation at ASCO 2007, Chicago, IL, USA. ; 2009 [accessed 15.05.09].
49. Bhojani N., Jeldres C., Patard J.J., et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53 (2008) 917-930
50. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5 (1982) 649-655
51. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, editor. Evaluation of chemotherapeutic agents. New York: Columbia University Press; 1949. p. 199-205.
52. Coebergh J.W., Janssen-Heijnen M.L., Post P.N., and Razenberg P.P. Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993-1996. J Clin Epidemiol 52 (1999) 1131-1136
53. Grunwald V., Heinzer H., and Fiedler W. Managing side effects of angiogenesis inhibitors in renal cell carcinoma. Onkologie 30 (2007) 519-524
54. Laber D.A. Risk factors, classification, and staging of renal cell cancer. Med Oncol 23 (2006) 443-454
55. Maroto-Rey P., and Villavincencio H. Sorafenib: tolerance in patients on chronic haemodialysis. Oncology 74 (2008) 245-246
56. Khosravan R., Toh M., LaFargue J., Ni G., and Bello C. Sunitinib pharmacokinetic (PK) and safety data in subjects with renal impairment and on hemodialysis. J Clin Oncol 26 Suppl. (2008) 131s [Abstract 2578]
57. Kirchner G.I., Meier-Wiedenbach I., and Manns M.P. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 43 (2004) 83-95
58. Rathmell K, Amin C, Wallen E, Pruthi R. Neoadjuvant therapy with sorafenib for locally advanced renal cell carcinoma (RCC). ASCO GU 2008. ; 2009 [accessed 15.05.09].
59. Negrier S, Perol D, Ravaud A, et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma (MRCC) of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. J Clin Oncol 2005;23(Suppl.):380s [Abstract 4511].
60. Proleukin summary of product characteristics. ; 2009 [accessed 15.05.09].
61. Roferon-A summary of product characteristics. ; 2009 [accessed 15.05.09].
62. Maroto-Rey P, Bellmunt J, Trigo JM, et al. First-line phase II trial of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma unsuitable for cytokine treatment. J Clin Oncol 2007;25(Suppl.):661s [Abstract 15640].
63. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 2505-2512
64. Dham A, Dudek AZ. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. J Clin Oncol 2007;25(Suppl.):261s [Abstract 2506].
65. Sablin M.P., Negrier S., Ravaud A., et al. Sequential use of sorafenib and sunitinib in renal cancer. J Urol 182 (2009) 29-34
66. Shepard DR, Rini BI, Garcia JA, et al. A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab. J Clin Oncol 2008;26(Suppl.):280s [Abstract 5123].
67. Tamaskar I., Garcia J.A., Elson P., et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 179 (2008) 81-86
68. Rini BI. Clinical prognostic and predictive markers for metastatic RCC therapeutic choices. Presentation at ASCO 2008, Chicago, IL, USA. ; 2009 [accessed 15.05.09].
69. Bukowski R., Cella D., Gondek K., and Escudier B. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 30 (2007) 220-227
70. Parasuraman S, Hudes G, Levy D, et al. Comparison of quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-α (IFN) or the combination of IFN+TEMSR. J Clin Oncol 2007;25(Suppl.):247s [Abstract 5049].